Login to Your Account



Alexion Defies Biotech's Slow Sales Trend; Beats Estimates

By Jennifer Boggs


Friday, July 22, 2011
Alexion Pharmaceuticals Inc. wowed investors on its earnings yet again, with second-quarter revenues that soundly beat expectations and prompted the Cheshire, Conn.-based firm to raise for the second time its 2011 sales guidance for paroxysmal nocturnal hemoglobinuria (PNH) drug Soliris (eculizumab).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription